Production (Stage)
Claritas Pharmaceuticals, Inc.
CLAZF
$0.00
$0.000.00%
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.57M | 1.88M | 1.70M | 1.90M | 2.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -770.00K | -462.00K | -643.00K | -247.00K | 2.28M |
| Operating Income | 770.00K | 462.00K | 643.00K | 247.00K | -2.28M |
| Income Before Tax | -4.46M | -4.58M | -4.08M | 12.63M | 4.73M |
| Income Tax Expenses | -420.00K | -420.00K | -420.00K | 45.00K | -18.00K |
| Earnings from Continuing Operations | -4.04 | -4.16 | -3.66 | 12.58 | 4.75 |
| Earnings from Discontinued Operations | -680.00K | -1.15M | -8.37M | -8.37M | -8.37M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.72M | -5.31M | -12.03M | 4.21M | -3.62M |
| EBIT | 770.00K | 462.00K | 643.00K | 247.00K | -2.28M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.16 | -0.18 | -0.45 | 0.17 | -0.13 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | 0.02 | 0.00 |
| EPS Diluted | -0.16 | -0.18 | -0.45 | 0.17 | -0.13 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | 0.02 | 0.00 |
| Average Basic Shares Outstanding | 123.67M | 115.35M | 108.21M | 106.75M | 106.14M |
| Average Diluted Shares Outstanding | 123.67M | 115.35M | 108.21M | 106.75M | 106.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |